Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.
BACKGROUND
Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment.


OBJECTIVE
To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors.


METHODS
Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmö, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP) and underwent follow-up until 2006 using the Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death).


METHODS
Incident cardiovascular and coronary events.


RESULTS
During median follow-up of 12.8 years, there were 418 cardiovascular and 230 coronary events. Models with conventional risk factors had C statistics of 0.758 (95% confidence interval [CI], 0.734 to 0.781) and 0.760 (0.730 to 0.789) for cardiovascular and coronary events, respectively. Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased the C statistic by 0.007 (P = .04) and 0.009 (P = .08), respectively. The proportion of participants reclassified was modest (8% for cardiovascular risk, 5% for coronary risk). Net reclassification improvement was nonsignificant for cardiovascular events (0.0%; 95% CI, -4.3% to 4.3%) and coronary events (4.7%; 95% CI, -0.76% to 10.1%). Greater improvements were observed in analyses restricted to intermediate-risk individuals (cardiovascular events: 7.4%; 95% CI, 0.7% to 14.1%; P = .03; coronary events: 14.6%; 95% CI, 5.0% to 24.2%; P = .003). However, correct reclassification was almost entirely confined to down-classification of individuals without events rather than up-classification of those with events.


CONCLUSIONS
Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events.
Melander
Olle
O
Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö University Hospital, SE 205 02 Malmö, Sweden. olle.melander@med.lu.se
Newton-Cheh
Christopher
C
Almgren
Peter
P
Hedblad
Bo
B
Berglund
Göran
G
Engström
Gunnar
G
Persson
Margaretha
M
Smith
J Gustav
JG
Magnusson
Martin
M
Christensson
Anders
A
Struck
Joachim
J
Morgenthaler
Nils G
NG
Bergmann
Andreas
A
Pencina
Michael J
MJ
Wang
Thomas J
TJ
D053607:Adrenomedullin / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology*; D015331:Cohort Studies; D055316:Cystatin C / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors
D015415:Biomarkers; D055316:Cystatin C; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D053607:Adrenomedullin; C087423:prodepin; D009320:Atrial Natriuretic Factor; D002097:C-Reactive Protein